Salesforce Shares Surge as AI Demand Powers Q2 Earnings Beat 
BNP Paribas, KB Kookmin Eye $2 Billion Techcombank Stake 
Australia’s Big Four Banks Face Mortgage Slowdown as Valuations Draw Scrutiny 
Luxshare Shares Rise as First-Half Profit Jumps 18% 
Yindjibarndi Appeals Fortescue Mining Compensation Ruling 
Nvidia Options Price in $280 Billion Earnings Swing 
U.S. Probes Apex Logistics Over Nvidia AI Chip Shipments to China 
OpenAI Data Center Chief Chris Malone Exits Ahead of Planned 2027 Listing 
Bathla Group Hires Administrators as Australia Housing Slump Deepens 
Mercer International Stock Surges 45% on C$20 Million Canada Funding 
Trump Buys SpaceX Shares After Record IPO 
Meta Agrees to $18 Billion Settlement, Tightens Teen Social Media Rules 
Nvidia Reportedly Eyes $13 Billion Hugging Face Acquisition 
HP Stock Drops 9% Despite Q3 Earnings Beat and Raised 2026 Outlook 
Google Expands Gemini Enterprise With AI Tools for Legal Sector 
SK Biopharmaceuticals Secures Global Rights to Biohaven Epilepsy Drug Opakalim 
Add as a preferred source on Google
Sanofi, the French pharmaceutical company, will be helping Moderna with the production of COVID-19 vaccines. The move was made in an effort to allow the American pharmaceutical and biotechnology firm to fulfill its orders and meet the demand for its shots.
Sanofi confirms production of Moderna shots
On Monday, April 26, Sanofi said that it has joined hands with the Massachusetts-headquartered biotech firm so it can provide assistance with filling vials and finish the packaging of up to 200 million doses as the demand for the Moderna COVID-19 vaccine is high.
Sanofi will be manufacturing the shots in its facility in Ridgefield, New Jersey. While the French company shared some info about its latest partnership with Moderna, it did not disclose any detail regarding the financial aspect of their deal, as per CNBC.
This is the third contract that Sanofi was able to secure since the start of this year. It previously signed a deal with Pfizer/BioNTech, to help them with supplying more than 125 million doses of coronavirus shots. The company also pledged to complete the filling and packing of Johnson & Johnson vaccines, and it must churn out at least 12 million doses per month.
Sanofi’s contribution in fulfilling Moderna’s COVID-19 vaccine supply will begin in September. While it has many deals to work on, the company is also busy in the development of its own vaccines in partnership with GlaxoSmithKline and another one with Translate Bio.
Sanofi aims to fill the bill for vaccines in the U.S.
The Wall Street Journal reported that based on the info coming from Sanofi’s spokesman, the finished doses of Moderna vaccines are for the U.S. supply where Moderna has an agreement until April 2022.
Meanwhile, Novartis AG and Merck Co. are also helping other makers of the coronavirus vaccines by forming agreements for production. The collaborations among the manufacturers are a collective effort to increase production so every nation in the world can have the doses they need.
Finally, Moderna is planning to distribute a total of 300 million doses of COVID-19 shots in the U.S. by the end of July. The delivery is projected to help President Biden achieve his goal of having the majority of American adults vaccinated by summer.
